Black and Low-Income Patients with Multiple Myeloma More Likely to Experience Treatment Delays, Study Finds

Multiple myeloma, which is the overgrowth of malignant plasma cells in the bone marrow, is characterized by hypercalcemia, renal failure, anemia and bone damage.

While some people may have asymptomatic multiple myeloma for some time, others may experience symptoms such as bone pain, bone weakness, and increased bone fractures.

Current treatment options have improved survival rates but have not provided a cure. Eventually, initial therapies stop working, and many patients relapse.

Today, therapy options can include novel targeted therapies, bispecific antibodies, and even chimeric antigen receptor T (CAR T)-cell therapy.

Although not all cases of multiple myeloma are symptomatic, timely treatment initiation is essential for preserving organ function and preventing complications, such as